Brazil suspended its decision to import four million doses of Covaxin


Posted on 29 July 2021


For Illustration Purpose Only.

Brazil has put off its decision to import four million doses of Bharat Biotech's COVID-19 vaccine Covaxin into the nation, following the suspension of intended clinical trials and a request for Emergency Use Authorisation. According to a statement released by the Brazilian National Health Surveillance Agency, Anvisa's Collegiate Board decided on Tuesday to suspend the exceptional and temporary authorization for the import and distribution of Covaxin after Bharat Biotech informed the South American government of the termination of its agreement with its Brazilian partners.

Bharat Biotech announced on July 23 that it has terminated its agreement with Precisa Medicamentos and Envixia Pharmaceuticals LLC for the Brazilian market of its COVID-19 vaccine Covaxin. Brazil never imported the vaccine, despite the fact that it was authorised for exceptional and temporary importation on June 4 at the ninth Extraordinary Meeting of the Collegiate Board of Anvisa. While announcing the termination of its deal with its Brazilian partners, Bharat Biotech stated that it will continue to work assiduously with Anvisa to complete the regulatory clearance process for Covaxin.


Key Points

  • Brazil has postponed its decision to import four million doses of Bharat Biotech's COVID-19 vaccine Covaxin into the nation, following the suspension of intended clinical trials and a request for Emergency Use Authorisation. 

  • While announcing the termination of its deal with its Brazilian partners, Bharat Biotech stated that it will continue to work assiduously with Anvisa to complete the regulatory clearance process for Covaxin.